Clinical trial
A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and…
NCT00490646 · R-Pharm, Industry · Completed
Key facts
| NCT number | NCT00490646 |
|---|---|
| Title | A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and/or Metastatic Breast Cancer |
| Official title | Randomized Phase II Study of Ixabepilone Plus Trastuzumab vs. Docetaxel Plus Trastuzumab in Female Subjects With Her2+ Locally Advanced and/or Metastatic Breast Cancer |
| Lead sponsor | R-Pharm, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Breast Cancer |
| Intervention type | Drug |
| Interventions | ixabepilone, docetaxel, trastuzumab |
| Enrollment | 50 |
| Start date | Feb 1, 2008 |
| Primary completion | Jun 1, 2011 |
| Completion | Nov 1, 2011 |
| First posted | Jun 25, 2007 |
| Last update posted | Mar 10, 2016 |
| Countries | France, Greece, Italy, Spain, Turkey (Türkiye) |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: